AP2214A - Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors. - Google Patents

Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors.

Info

Publication number
AP2214A
AP2214A AP2006003480A AP2006003480A AP2214A AP 2214 A AP2214 A AP 2214A AP 2006003480 A AP2006003480 A AP 2006003480A AP 2006003480 A AP2006003480 A AP 2006003480A AP 2214 A AP2214 A AP 2214A
Authority
AP
ARIPO
Prior art keywords
pyrrolo
kinase inhibitors
pyrazole derivatives
derivatives active
active
Prior art date
Application number
AP2006003480A
Other languages
English (en)
Other versions
AP2006003480A0 (en
Inventor
Daniele Fancelli
Barbra Forte
Jurgen Moll
Mario Varasi
Paolo Vianello
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of AP2006003480A0 publication Critical patent/AP2006003480A0/xx
Application granted granted Critical
Publication of AP2214A publication Critical patent/AP2214A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2006003480A 2003-07-09 2004-07-08 Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors. AP2214A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48581403P 2003-07-09 2003-07-09

Publications (2)

Publication Number Publication Date
AP2006003480A0 AP2006003480A0 (en) 2006-02-28
AP2214A true AP2214A (en) 2011-03-04

Family

ID=34062099

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003480A AP2214A (en) 2003-07-09 2004-07-08 Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors.

Country Status (42)

Country Link
US (2) US7141568B2 (xx)
EP (1) EP1644376B1 (xx)
JP (1) JP4728232B2 (xx)
KR (1) KR101075711B1 (xx)
CN (1) CN100564380C (xx)
AP (1) AP2214A (xx)
AR (1) AR050045A1 (xx)
AT (1) ATE480540T1 (xx)
AU (1) AU2004255347B2 (xx)
BR (1) BRPI0411868B8 (xx)
CA (1) CA2531759C (xx)
CR (1) CR8171A (xx)
CY (1) CY1110832T1 (xx)
DE (1) DE602004029045D1 (xx)
DK (1) DK1644376T3 (xx)
DO (1) DOP2004000949A (xx)
EA (1) EA009462B1 (xx)
EC (1) ECSP056246A (xx)
ES (1) ES2349780T3 (xx)
GE (1) GEP20084395B (xx)
GT (2) GT200400133A (xx)
HK (1) HK1089769A1 (xx)
HN (1) HN2004000232A (xx)
IL (1) IL172923A (xx)
IS (1) IS2843B (xx)
MA (1) MA28064A1 (xx)
ME (1) MEP51908A (xx)
MX (1) MXPA06000362A (xx)
MY (1) MY139072A (xx)
NO (1) NO332361B1 (xx)
NZ (1) NZ544514A (xx)
PA (1) PA8606201A1 (xx)
PE (1) PE20050325A1 (xx)
PL (1) PL1644376T3 (xx)
PT (1) PT1644376E (xx)
RS (2) RS20060004A (xx)
SI (1) SI1644376T1 (xx)
TN (1) TNSN06009A1 (xx)
TW (1) TWI343382B (xx)
UA (1) UA81682C2 (xx)
WO (1) WO2005005427A1 (xx)
ZA (1) ZA200600095B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4555547B2 (ja) * 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8067591B2 (en) * 2005-01-10 2011-11-29 Agouron Pharmaceuticals, Inc. Pyrrolopyrazole, potent kinase inhibitors
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
WO2010009967A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
US20100022553A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
CN102105148B (zh) * 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
ES2468391T3 (es) 2008-12-22 2014-06-16 Millennium Pharmaceuticals, Inc. Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20
BR112014014276A2 (pt) 2011-12-12 2017-06-13 Dr Reddys Laboratories Ltd composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
US9394305B2 (en) 2014-06-23 2016-07-19 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024006424A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Kras g12c inhibitor for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717380B1 (fr) * 1994-03-15 1996-04-26 Oreal Compositions cosmétiques contenant un mélange synergétique de polymères conditionneurs.
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19932144A1 (de) * 1999-07-09 2001-01-11 Basf Ag Mikrokapselzubereitungen und Mikrokapseln enthaltende Wasch- und Reinigungsmittel
ES2249270T3 (es) 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
JP2004517840A (ja) 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
ES2357502T3 (es) 2001-09-26 2011-04-27 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen.
JP2005536526A (ja) 2002-07-25 2005-12-02 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロ−ピラゾール類、その製造方法、およびそれを含有する薬学的組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
NZ544514A (en) 2009-07-31
ECSP056246A (es) 2006-04-19
NO20060113L (no) 2006-04-05
PE20050325A1 (es) 2005-05-17
TWI343382B (en) 2011-06-11
AU2004255347B2 (en) 2010-04-08
IL172923A0 (en) 2006-06-11
CN1820009A (zh) 2006-08-16
BRPI0411868B8 (pt) 2021-05-25
DOP2004000949A (es) 2005-01-15
IL172923A (en) 2011-09-27
NO332361B1 (no) 2012-09-03
CA2531759C (en) 2013-04-02
EP1644376B1 (en) 2010-09-08
PA8606201A1 (es) 2005-08-04
HK1089769A1 (en) 2006-12-08
AR050045A1 (es) 2006-09-27
ZA200600095B (en) 2007-01-31
GT200400133A (es) 2005-04-18
BRPI0411868B1 (pt) 2019-11-12
CA2531759A1 (en) 2005-01-20
RS52155B (en) 2012-08-31
TW200510385A (en) 2005-03-16
AP2006003480A0 (en) 2006-02-28
EA200600209A1 (ru) 2006-06-30
CY1110832T1 (el) 2015-06-10
JP2009513525A (ja) 2009-04-02
ES2349780T3 (es) 2011-01-11
MY139072A (en) 2009-08-28
US7582628B2 (en) 2009-09-01
PL1644376T3 (pl) 2011-03-31
EP1644376A1 (en) 2006-04-12
MEP51908A (en) 2011-05-10
GT200400133AA (es) 2007-07-10
MA28064A1 (fr) 2006-08-01
RS20060004A (xx) 2008-06-05
HN2004000232A (es) 2011-01-17
DK1644376T3 (da) 2011-01-03
DE602004029045D1 (de) 2010-10-21
CN100564380C (zh) 2009-12-02
EA009462B1 (ru) 2007-12-28
MXPA06000362A (es) 2006-03-28
KR101075711B1 (ko) 2011-10-21
TNSN06009A1 (fr) 2007-10-03
WO2005005427A1 (en) 2005-01-20
IS8192A (is) 2005-12-22
JP4728232B2 (ja) 2011-07-20
KR20060033001A (ko) 2006-04-18
US20050032839A1 (en) 2005-02-10
IS2843B (is) 2013-08-15
UA81682C2 (xx) 2008-01-25
GEP20084395B (en) 2008-06-10
US7141568B2 (en) 2006-11-28
CR8171A (es) 2006-08-09
BRPI0411868A (pt) 2006-08-08
AU2004255347A1 (en) 2005-01-20
ATE480540T1 (de) 2010-09-15
US20060276471A1 (en) 2006-12-07
SI1644376T1 (sl) 2010-11-30
PT1644376E (pt) 2010-09-24

Similar Documents

Publication Publication Date Title
AP2214A (en) Pyrrolo [3,4-c] pyrazole derivatives active as kinase inhibitors.
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
AP2006003486A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors.
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
PL392790A1 (pl) Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy
HK1057890A1 (en) Pyrazole compounds useful as protein kinase inhibitors.
MXPA03005605A (es) Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
ZA200606179B (en) 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors